Ildong Holdings Co Ltd

Ildong Holdings exhibits a highly leveraged capital structure, with total liabilities of KRW 823.97 billion and total equity of KRW 30.96 billion, resulting in a debt-to-equity ratio of 12.23. The company's liquidity position is weak, as evidenced by a current ratio of 0.51 and negative free cash flow of KRW -3.27 billion. Despite holding KRW 57.40 billion in cash and equivalents, the firm's long-term debt of KRW 378.50 billion exceeds its net cash position, raising concerns about its ability to meet long-term obligations.

Profitability metrics are sharply negative, with a net loss of KRW -6.12 billion and an operating loss of KRW -3.82 billion. Return on equity is -19.77%, and return on assets is -0.72%, both significantly below industry norms for pharmaceutical firms. The company's gross profit margin of 35.14% (KRW 56.87 billion on KRW 161.86 billion in revenue) is also below the median for its industry.

Geographically, Ildong Holdings is heavily concentrated in the South Korean market, with no disclosed international revenue segments. This concentration increases exposure to domestic regulatory and economic risks. The company does not report segment-level revenue breakdowns, but its product portfolio is entirely focused on prescription pharmaceuticals.

The company's growth trajectory is under pressure, with a net loss in the most recent reporting period. Historical revenue data is not provided, but the current operating and net losses suggest a contraction in profitability. The risk assessment flags a negative net cash position after subtracting total debt, which could constrain growth initiatives.

The risk profile is elevated, with a medium liquidity risk and a debt-to-equity ratio that is 12 times the equity base. The company's dilution risk is currently low, but the high leverage and negative cash flow could necessitate future equity or debt financing, which would increase dilution potential. No recent events or filings are disclosed that would alter this risk outlook.

No recent events, such as earnings calls, regulatory filings, or strategic announcements, are disclosed in the available data. The absence of recent disclosures limits visibility into management's strategic direction or response to the current financial challenges.

Il Dong Holdings Co Ltd (000230.KS) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals. This taxonomic update provides a clearer definition of the company’s operational focus, establishing a baseline for sector-specific analysis and peer comparison. Alongside this classification, the company’s risk profile has been initialized with specific assessments. Dilution risk is currently rated as low, suggesting that the potential for existing shareholders to see their ownership stakes reduced through new share issuance is minimal. Conversely, liquidity risk has been assessed at a medium level. This indicates that while the company is not facing immediate distress, there may be moderate constraints on its ability to meet short-term obligations or trade shares without significant price impact, warranting ongoing monitoring. These updates reflect a foundational step in the company’s analytical profile, moving from unclassified status to a defined sector and risk framework. With no current analyst coverage or index membership recorded, these internal metrics serve as the primary indicators for evaluating Il Dong Holdings’ financial stability and market positioning. [doc:000230.ks-ha-financials]

Free cash flow improved significantly to 30.5 billion KRW in FY0, reversing the negative trend from prior years.

Long-term debt decreased substantially to 205.4 billion KRW in FY0, reducing leverage compared to previous periods.

Cash conversion ratio of 1.22 exceeds the pharmaceutical cohort median of 0.95, indicating efficient cash generation.

Gross profit remained robust at 225.2 billion KRW in FY0, maintaining strong top-line profitability despite revenue declines.

Dilution risk is assessed as low, suggesting limited immediate threat to existing shareholder equity value.

The company faces high credit risk, indicating significant concerns regarding its ability to meet financial obligations.